NABCO Receives Support From Wal-Mart Foundation for In-Store Breast Health Program

Publication
Article
OncologyONCOLOGY Vol 11 No 9
Volume 11
Issue 9

The National Alliance of Breast Cancer Organizations (NABCO)-in a partnership with Oil of Olay-has received a $50,000 grant from the Wal-Mart Foundation in support of breast cancer awareness.

The National Alliance of Breast Cancer Organizations (NABCO)—in a partnershipwith Oil of Olay—has received a $50,000 grant from the Wal-Mart Foundationin support of breast cancer awareness.

Through free educational brochures made available in more than 3,000Oil of Olay product displays in Wal-Mart stores, NABCO is offering eachwoman help in establishing her own breast health program. Wal-Mart helpedto educate women by providing an opportunity to pick up a brochure or purchasean Oil of Olay skin care product labeled with NABCO's toll-free help line—1-800-719-9154.

"The Wal-Mart Foundation is proud to participate in supportingincreased awareness of an important health issue for women," saidEmerson Goodwin, Director of the Wal-Mart Foundation. "We hope torepeat this program in years to come."

NABCO's Executive Director Amy Langer, herself a breast cancer survivor,commented, "We are delighted by this new opportunity to reach women,and are grateful for the Wal-Mart Foundation's generous support of NABCO'soutreach programs. By bringing breast health information to women wherethey shop, we hope to make real progress in the fight against breast cancer."

In addition to supporting breast cancer education, in association withits vendors, stores, and customers, this year the Wal-Mart Foundation,based in Bentonville, Arkansas, will contribute nearly $81 million to localand national nonprofit organizations.

Recent Videos
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content